Entering text into the input field will update the search result below

Novo Nordisk once-weekly insulin icodec better than daily Tresiba in late-stage study

Sep. 22, 2022 5:32 AM ETNovo Nordisk A/S (NVO) StockBy: Ravikash Bakolia, SA News Editor2 Comments

Novo Nordisk Canada Inc head office in Mississauga, Ontario, Canada.

JHVEPhoto

Novo Nordisk (NVO) said new data from a phase 3a trial showed that more people with type 2 diabetes achieved blood sugar target with once-weekly insulin icodec compared with its own once-daily therapy Tresiba (insulin degludec).

The Danish company reported

Recommended For You

About NVO Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
NVO--
Novo Nordisk A/S